Halozyme Therapeutics Inc. held its Annual Meeting of Stockholders on May 1, 2025. The stockholders voted on the election of two Class III directors, Jeffrey W. Henderson and Helen I. Torley, both of whom were elected. Additionally, a proposal to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-25-000022), on May 02, 2025, and is solely responsible for the information contained therein.